Charles A Poon, MD
Internal Medicine · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Hospitals listed: Kaiser Foundation Hospital-Santa Clara. That is not proof they admit you there this week.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Poon’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence A103158 · Current
Licensed to practise in California · since 2008 · expires 2028-02-29 · Loma Linda University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Kaiser Foundation Hospital-Santa ClaraSanta Clara, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Kaiser Permanente, which runs 41 hospitals in 3 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.38, Oct 2024 – Sep 2025
See every measure and the patient survey for Kaiser Foundation Hospital-Santa Clara
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 1 the same, 1 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.38 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0 to 2.09) · 181 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.61 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 312 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 910 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 1,036 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.53 (2.03 to 7.03) · 235 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.25) · 83 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.5 (0.82 to 4.18) · 178 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.73 (3.81 to 19.64) · 74 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.31 (1.3 to 9.32) · 94 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.28) · 37 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.34 (0 to 1.34) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.72 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.049 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.598 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.926 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13 · 589 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.7 · 828 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 107.6 · 27 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 642 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 7.8 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 181 cases | None | Jul 2023 – Jun 2025 |
What patients said (572 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$1,813
Medicare paid this office $1,813 for 15 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
15 Original Medicare patients in 2024. Average age 73 · Health risk score 3.84. Sicker patients than 9 in 10 peers; the typical internal medicine clinician is at 1.76.
The office billed $6,443, Medicare allowed $2,386 and paid $1,813; for 18 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 15 | 18 | 73 | 3.84 | $6,443 | $1,813 |
| 2023 | 11 | 20 | 68 | 3.23 | $9,463 | $1,808 |
| 2022 | 23 | 41 | 72 | 2.72 | $15,874 | $2,879 |
| 2021 | 15 | 38 | 66 | 4.18 | $7,613 | $2,645 |
| 2020 | 14 | 31 | 73 | 3.14 | $5,292 | $2,262 |
| 2018 | 20 | 40 | 72 | 2.98 | $8,825 | $2,979 |
| 2017 | 17 | 36 | 68 | 3.27 | $9,053 | $2,780 |
| 2016 | 15 | 32 | 69 | 2.74 | $6,931 | $2,023 |
| 2015 | 18 | 37 | 64 | 4.30 | $9,852 | $2,969 |
| 2014 | 206 | 571 | 74 | 2.60 | $225,856 | $52,363 |
| 2013 | 88 | 221 | 75 | 2.40 | $88,807 | $20,277 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2020: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,529 | $66 |
2014: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 82 | $17,144 | $89 |
| Critical care, first 30-74 minutes | 32 | $10,297 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 72 | $8,912 | $61 |
| Return visit (30+ min) | 43 | $3,590 | $83 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,529 | $118 |
| Short return visit (20+ min) | 33 | $3,160 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,318 | $166 |
2013: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $5,766 | $60 |
| Critical care, first 30-74 minutes | 15 | $4,045 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $3,547 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,532 | $169 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,259 | $114 |
Drugs they prescribed that Part D paid
$133,996
Pharmacies billed $133,996 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
307 generic and fewer than 11 brand-name prescriptions · $133,996 in drug cost · 43 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Spiriva Respimat | 31 | $27,110 | $875 |
| Pirfenidone | 53 | $13,962 | $263 |
| Breyna | 54 | $7,182 | $133 |
| Alvesco | 17 | $1,932 | $114 |
| Methylphenidate Er | 12 | $1,405 | $117 |
See all 12 drugs
| Spiriva Respimat | 31 | $27,110 | $875 |
| Pirfenidone | 53 | $13,962 | $263 |
| Breyna | 54 | $7,182 | $133 |
| Alvesco | 17 | $1,932 | $114 |
| Methylphenidate Er | 12 | $1,405 | $117 |
| Ramelteon | 16 | $1,316 | $82 |
| Doxepin | 11 | $726 | $66 |
| Prednisone | 24 | $333 | $14 |
| Albuterol Sulfate Hfa | 15 | $323 | $22 |
| Gabapentin | 27 | $312 | $12 |
| Amoxicillin-Clavulanate Potass | 12 | $209 | $17 |
| Pregabalin | 12 | $105 | $9 |
Year by year
| 2024 | 407 | 108 | None | None | $133,996 |
| 2023 | 386 | 110 | 0% (0) | None | $124,097 |
| 2022 | 402 | 132 | 0% (0) | None | $263,184 |
| 2021 | 305 | 96 | 0% (0) | 54% | $197,618 |
| 2020 | 364 | 103 | 0% (0) | 49% | $211,280 |
| 2019 | 438 | 153 | 0% (0) | 61% | $349,207 |
| 2018 | 563 | 137 | 0% (0) | 62% | $322,832 |
| 2017 | 721 | 141 | 0% (0) | 56% | $298,183 |
| 2016 | 570 | 143 | 0% (0) | 55% | $183,582 |
| 2015 | 663 | 168 | 0% (0) | 53% | $164,417 |
| 2014 | 332 | 114 | 0% (0) | 62% | $53,916 |
| 2013 | 205 | 45 | 0% (0) | 75% | $44,495 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Spiriva Respimat | 36 | $28,901 | $803 |
| Pirfenidone | 45 | $21,754 | $483 |
| Stiolto Respimat | 23 | $8,928 | $388 |
| Symbicort | 28 | $7,973 | $285 |
| Prednisone | 31 | $497 | $16 |
| Albuterol Sulfate Hfa | 25 | $464 | $19 |
| Gabapentin | 20 | $217 | $11 |
| Amoxicillin-Clavulanate Potass | 13 | $213 | $16 |
| Sulfamethoxazole-Trimethoprim | 12 | $80 | $7 |
2022: 14 drugs
| Esbriet | 11 | $130,127 | $11,830 |
| Pirfenidone | 22 | $33,583 | $1,527 |
| Spiriva Respimat | 40 | $26,667 | $667 |
| Symbicort | 22 | $7,529 | $342 |
| Stiolto Respimat | 15 | $7,250 | $483 |
| Ramelteon | 16 | $2,865 | $179 |
| Wixela Inhub | 13 | $2,736 | $210 |
| Alvesco | 15 | $1,809 | $121 |
| Mycophenolate Mofetil | 11 | $1,162 | $106 |
| Albuterol Sulfate Hfa | 32 | $721 | $23 |
| Prednisone | 24 | $340 | $14 |
| Azithromycin | 12 | $270 | $22 |
| Amoxicillin-Clavulanate Potass | 14 | $229 | $16 |
| Gabapentin | 12 | $124 | $10 |
2021: 9 drugs
| Spiriva Respimat | 27 | $17,933 | $664 |
| Alvesco | 19 | $3,018 | $159 |
| Symbicort | 11 | $2,747 | $250 |
| Wixela Inhub | 11 | $1,499 | $136 |
| Methylphenidate Er (La) | 11 | $1,467 | $133 |
| Prednisone | 33 | $969 | $29 |
| Albuterol Sulfate Hfa | 34 | $782 | $23 |
| Amoxicillin-Clavulanate Potass | 11 | $205 | $19 |
| Gabapentin | 11 | $139 | $13 |
2020: 9 drugs
| Spiriva Respimat | 46 | $17,248 | $375 |
| Atrovent Hfa | 12 | $8,276 | $690 |
| Advair Diskus | 23 | $5,464 | $238 |
| Ventolin Hfa | 26 | $1,996 | $77 |
| Ramelteon | 13 | $1,390 | $107 |
| Prednisone | 44 | $1,112 | $25 |
| Azithromycin | 15 | $461 | $31 |
| Montelukast | 22 | $166 | $8 |
| Doxycycline Monohydrate | 11 | $144 | $13 |
2019: 9 drugs
| Esbriet | 12 | $108,421 | $9,035 |
| Spiriva Respimat | 70 | $26,679 | $381 |
| Advair Diskus | 47 | $11,648 | $248 |
| Stiolto Respimat | 13 | $7,575 | $583 |
| Ventolin Hfa | 47 | $3,812 | $81 |
| Azithromycin | 14 | $606 | $43 |
| Prednisone | 28 | $448 | $16 |
| Doxycycline Monohydrate | 23 | $321 | $14 |
| Fluticasone Propionate | 16 | $252 | $16 |
2018: 16 drugs
| Letairis | 11 | $111,150 | $10,105 |
| Stiolto Respimat | 54 | $41,388 | $766 |
| Spiriva Respimat | 71 | $26,445 | $372 |
| Advair Diskus | 60 | $18,490 | $308 |
| Dulera | 14 | $13,598 | $971 |
| Daliresp | 12 | $5,480 | $457 |
| Ventolin Hfa | 49 | $3,461 | $71 |
| Sildenafil | 12 | $2,038 | $170 |
| Qvar | 12 | $1,139 | $95 |
| Azithromycin | 32 | $1,075 | $34 |
| Ethambutol | 12 | $929 | $77 |
| Rifampin | 13 | $832 | $64 |
| Prednisone | 30 | $595 | $20 |
| Doxycycline Monohydrate | 28 | $379 | $14 |
| Fluticasone Propionate | 25 | $373 | $15 |
| Famotidine | 11 | $167 | $15 |
2017: 17 drugs
| Opsumit | 12 | $107,565 | $8,964 |
| Spiriva Respimat | 121 | $44,059 | $364 |
| Dulera | 55 | $14,635 | $266 |
| Advair Diskus | 34 | $13,866 | $408 |
| Stiolto Respimat | 13 | $10,901 | $839 |
| Serevent Diskus | 15 | $5,826 | $388 |
| Ventolin Hfa | 70 | $3,367 | $48 |
| Qvar | 17 | $1,801 | $106 |
| Ethambutol | 23 | $1,334 | $58 |
| Prednisone | 48 | $1,060 | $22 |
| Azithromycin | 52 | $1,029 | $20 |
| Rifampin | 19 | $978 | $51 |
| Doxycycline Monohydrate | 39 | $605 | $16 |
| Montelukast | 24 | $462 | $19 |
| Fluticasone Propionate | 21 | $307 | $15 |
| Amoxicillin-Clavulanate Potass | 12 | $271 | $23 |
| Furosemide | 13 | $105 | $8 |
2016: 14 drugs
| Opsumit | 11 | $86,587 | $7,872 |
| Spiriva Respimat | 93 | $28,003 | $301 |
| Advair Diskus | 33 | $20,314 | $616 |
| Dulera | 65 | $13,384 | $206 |
| Combivent Respimat | 12 | $7,400 | $617 |
| Amoxicillin-Clavulanate Potass | 24 | $2,711 | $113 |
| Ventolin Hfa | 37 | $1,585 | $43 |
| Azathioprine | 17 | $1,237 | $73 |
| Prednisone | 43 | $1,088 | $25 |
| Doxycycline Monohydrate | 43 | $737 | $17 |
| Azithromycin | 29 | $511 | $18 |
| Fluticasone Propionate | 22 | $352 | $16 |
| Montelukast | 15 | $305 | $20 |
| Levofloxacin | 12 | $121 | $10 |
2015: 16 drugs
| Spiriva | 86 | $38,749 | $451 |
| Advair Diskus | 32 | $27,268 | $852 |
| Dulera | 93 | $26,416 | $284 |
| Combivent Respimat | 19 | $10,885 | $573 |
| Spiriva Respimat | 19 | $5,999 | $316 |
| Amoxicillin-Clavulanate Potass | 24 | $2,220 | $92 |
| Qvar | 17 | $2,009 | $118 |
| Proair Hfa | 44 | $1,821 | $41 |
| Montelukast | 51 | $1,459 | $29 |
| Prednisone | 51 | $1,117 | $22 |
| Azithromycin | 29 | $900 | $31 |
| Doxycycline Monohydrate | 36 | $802 | $22 |
| Azathioprine | 13 | $733 | $56 |
| Fluticasone Propionate | 23 | $550 | $24 |
| Levofloxacin | 17 | $173 | $10 |
| Furosemide | 17 | $119 | $7 |
2014: 11 drugs
| Spiriva | 59 | $19,762 | $335 |
| Advair Diskus | 26 | $9,188 | $353 |
| Symbicort | 29 | $7,412 | $256 |
| Combivent Respimat | 15 | $5,892 | $393 |
| Dulera | 11 | $2,905 | $264 |
| Proair Hfa | 30 | $1,345 | $45 |
| Ventolin Hfa | 16 | $711 | $44 |
| Fluticasone Propionate | 16 | $343 | $21 |
| Montelukast | 12 | $267 | $22 |
| Prednisone | 24 | $208 | $9 |
| Azithromycin | 11 | $186 | $17 |
2013: 6 drugs
| Spiriva | 45 | $13,746 | $305 |
| Symbicort | 35 | $10,322 | $295 |
| Advair Diskus | 18 | $5,410 | $301 |
| Combivent Respimat | 14 | $3,601 | $257 |
| Proair Hfa | 17 | $1,048 | $62 |
| Azithromycin | 23 | $785 | $34 |
Money from drug and device companies
$150 in 2025
A payment is not proof that care is biased.
| Jazz Pharmaceuticals | Xywav | $150 | 1 payment
|
See the published payment
| Jazz Pharmaceuticals | Consulting · 2025-02-13 | Xywav | $150 |
Professional record
- NPI
- 1245475334
- Licence
- CA A103158California A103158: Current · expires 2028-02-29
- Trained
- Loma Linda University School of Medicine, 2006
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 4150 V St, Suite 3400, Sacramento, CA, 95817
- NPI first listed
- 2008-12-03
- NPI last updated
- 2022-02-11
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.